ASCO® 2026 Highlights: Presenter Vignettes
Videos
Day 1
Chinese University of Hong Kong
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Thomas Jefferson University Hospital
A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)–naive basal cell carcinoma of the head and neck.
University of Chicago Medicine
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
Gustave-Roussy Cancer Campus
The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.
Peter MacCallum Cancer Centre
Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
Day 2
Click one or more tumour names to filter results
BC Cancer
First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
MD Anderson Cancer Center
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC).
Queen Mary University of London
502
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
507
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.
Duke University Medical Center
Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
Peking University Cancer Hospital
Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.
Memorial Sloan Kettering Cancer Center
A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.
The Royal Marsden Hospital
Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
Duke Cancer Institute
Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
Barts Cancer Institute
Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.
Houston Methodist Academic Institute
Primary results from the triple-negative cohort of TBCRC-053 (P-RAD): A randomized trial of no, low, or high dose preoperative radiation with pembrolizumab and chemotherapy in node-positive breast cancer.
Washington University
Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.
UZ Leuven
NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC).
BC Cancer
Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Day 3
Click one or more tumour names to filter results
Massachusetts General Hospital Cancer Center
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma.
Memorial Sloan Kettering Cancer Center
Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
McGill University
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
Stanford University School of Medicine
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.
University Hospital Schleswig-Holstein
Prediction of axillary response in 5,262 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study.
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano & IFOM ETS - The AIRC Institute of Molecular Oncology
Effectiveness of first-line ET+CDK4/6i continuation beyond disease progression in a large cohort of patients with HR+/HER2− advanced breast cancer: Results from the multicenter, real-world, Italian study PALMARES-2.
Moffitt Cancer Center
A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.
Markey Cancer Center
Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.
MD Anderson Cancer Center
Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.
St. Olav's Hospital
Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
University Hospital Würzburg
Primary results of the BETTER-CARE trial: Implementation of a needs-adapted and individualized follow-up care after primary breast cancer.
Memorial Sloan Kettering Cancer Center
Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
Westmead and Blacktown Hospitals
Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
Thomas Jefferson University Hospital
Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.
Cleveland Clinic
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032901).
Toronto General Hospital
IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).
University of Alabama at Birmingham
External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.
Charité Universitaetsmedizin Berlin
Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.
MD Anderson Cancer Center
Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.
University College London Hospitals
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
Kyushu University Hospital
Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.
Day 4
Click one or more tumour names to filter results
Institut Català d'Oncologia
Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer.
Hospital del Mar Research Institute
Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).
Fred Hutch Cancer Center
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo).
Sarah Cannon Research Institute
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
Sarah Cannon Research Institute
Association of GLP-1 agonists with breast cancer incidence in women.
Istituto Nazionale Tumori IRCCS
The effects of Mediterranean diet, physical activity, and vitamin D on breast cancer recurrence and cardiometabolic health: A multicenter randomized trial.
MD Anderson Cancer Center
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).